Semin Liver Dis 2019; 39(01): 043-052
DOI: 10.1055/s-0038-1676098
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines?

Melody J. Xu
1   Department of Radiation Oncology, University of California San Francisco, San Francisco, California
,
Mary Feng
1   Department of Radiation Oncology, University of California San Francisco, San Francisco, California
› Author Affiliations
Further Information

Publication History

Publication Date:
07 December 2018 (online)

Abstract

Hepatocellular carcinoma (HCC) is a complex and diverse disease, with choice of treatment dependent on a patient's disease burden, location of disease, underlying liver function, and performance status. While radiation therapy (RT) was historically omitted from treatment algorithms, immense technological advances over the past several decades have enabled introduction of RT as an effective and safe treatment option for patients with HCC. Growing prospective and retrospective evidence supports the use of RT, particularly stereotactic body radiotherapy (SBRT), for a wide range of indications in HCC from locally advanced unresectable disease to bridge therapy for liver transplant candidates. SBRT is associated with excellent local control, even for patients refractory to or ineligible for other forms of locoregional therapy. Treatment is well-tolerated and associated with low rates of severe toxicity. Randomized trials are needed to define the role of SBRT in HCC treatment relative to other established locoregional treatments.

 
  • References

  • 1 Wong MCS, Jiang JY, Goggins WB. , et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep 2017; 7: 45846
  • 2 Baecker A, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev 2018; 27 (03) 205-212
  • 3 Burkhart RA, Pawlik TM. Staging and prognostic models for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Contr 2017; 24 (03) 1073274817729235
  • 4 Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19 (03) 329-338
  • 5 Pang TC, Lam VW. Surgical management of hepatocellular carcinoma. World J Hepatol 2015; 7 (02) 245-252
  • 6 Chen X, Liu HP, Li M, Qiao L. Advances in non-surgical management of primary liver cancer. World J Gastroenterol 2014; 20 (44) 16630-16638
  • 7 Bruix J, Sherman M. ; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (03) 1020-1022
  • 8 European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (04) 908-943
  • 9 Omata M, Cheng AL, Kokudo N. , et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11 (04) 317-370
  • 10 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol 2016; 22 (01) 7-17
  • 11 Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut Liver 2015; 9 (03) 267-317
  • 12 Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP. ; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB 2010; 12 (05) 313-320
  • 13 Pan CC, Kavanagh BD, Dawson LA. , et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010; 76 (3, Suppl) S94-S100
  • 14 Thariat J, Hannoun-Levi JM, Sun Myint A, Vuong T, Gérard JP. Past, present, and future of radiotherapy for the benefit of patients. Nat Rev Clin Oncol 2013; 10 (01) 52-60
  • 15 Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002; 53 (04) 810-821
  • 16 Ben-Josef E, Normolle D, Ensminger WD. , et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23 (34) 8739-8747
  • 17 Dawson LA, McGinn CJ, Normolle D. , et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18 (11) 2210-2218
  • 18 Choi C, Koom WS, Kim TH. , et al. A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2014; 90 (05) 1051-1060
  • 19 Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 2005; 25 (06) 1189-1196
  • 20 Seong J, Keum KC, Han KH. , et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 1999; 43 (02) 393-397
  • 21 Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. JAMA Oncol 2015; 1 (06) 756-765
  • 22 Zhang T, Zhao YT, Wang Z. , et al. Efficacy and safety of intensity-modulated radiotherapy following transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore) 2016; 95 (21) e3789
  • 23 Bae SH, Jang WI, Park HC. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. Oncotarget 2017; 8 (35) 59965-59976
  • 24 Bucci MK, Bevan A, Roach III M. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin 2005; 55 (02) 117-134
  • 25 Mann J, Ramakrishna R, Magge R, Wernicke AG. advances in radiotherapy for glioblastoma. Front Neurol 2018; 8: 748
  • 26 Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 1951; 102 (04) 316-319
  • 27 Tsang MW. Stereotactic body radiotherapy: current strategies and future development. J Thorac Dis 2016; 8 (Suppl 6): S517-S527
  • 28 Katsoulakis E, Kumar K, Laufer I, Yamada Y. Stereotactic body radiotherapy in the treatment of spinal metastases. Semin Radiat Oncol 2017; 27 (03) 209-217
  • 29 Doi H, Beppu N, Kitajima K, Kuribayashi K. Stereotactic body radiation therapy for liver tumors: current status and perspectives. Anticancer Res 2018; 38 (02) 591-599
  • 30 Meyer J, Singal AG. Stereotactic ablative radiotherapy for hepatocellular carcinoma: history, current status, and opportunities. Liver Transpl 2018; 24 (03) 420-427
  • 31 Murray LJ, Dawson LA. Advances in stereotactic body radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol 2017; 27 (03) 247-255
  • 32 Hata M, Tokuuye K, Sugahara S. , et al. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol 2006; 182 (12) 713-720
  • 33 Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer 2011; 117 (13) 3053-3059
  • 34 Bush DA, Smith JC, Slater JD. , et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int J Radiat Oncol Biol Phys 2016; 95 (01) 477-482
  • 35 Hong TS, Wo JY, Yeap BY. , et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016; 34 (05) 460-468
  • 36 He J, Zeng ZC, Fan J. , et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation. BMC Cancer 2011; 11: 492
  • 37 Kaizu T, Karasawa K, Tanaka Y. , et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. Am J Gastroenterol 1998; 93 (11) 2167-2171
  • 38 Choi Y, Kim J, Lee I, Seong J. Dose escalation using helical tomotherapy improves local control in spine metastases from primary hepatic malignancies. Liver Int 2014; 34 (03) 462-468
  • 39 Jung IH, Yoon SM, Kwak J. , et al. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma. Oncotarget 2017; 8 (09) 15182-15192
  • 40 Park ES, Kwon DH, Park JB. , et al. Gamma Knife surgery for treating brain metastases arising from hepatocellular carcinomas. J Neurosurg 2014; 121 (Suppl): 102-109
  • 41 Choi HJ, Cho BC, Sohn JH. , et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol 2009; 91 (03) 307-313
  • 42 Wang S, Wang A, Lin J. , et al. Brain metastases from hepatocellular carcinoma: recent advances and future avenues. Oncotarget 2017; 8 (15) 25814-25829
  • 43 Kang JK, Kim MS, Cho CK. , et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012; 118 (21) 5424-5431
  • 44 Jang WI, Kim MS, Bae SH. , et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 2013; 8: 250
  • 45 Baumann BC, Wei J, Plastaras JP. , et al. Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: high rates of local control with low toxicity. Am J Clin Oncol 2018
  • 46 Burak KW, Sherman M. Hepatocellular carcinoma: consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol 2015; 29 (04) 178-184
  • 47 Nault JC, Sutter O, Nahon P, Ganne-Carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol 2017; S0168-8278(17)32351-6
  • 48 Méndez Romero A, Wunderink W, Hussain SM. , et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol 2006; 45 (07) 831-837
  • 49 Lasley FD, Mannina EM, Johnson CS. , et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Pract Radiat Oncol 2015; 5 (05) e443-e449
  • 50 Wahl DR, Stenmark MH, Tao Y. , et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016; 34 (05) 452-459
  • 51 Kimura T, Aikata H, Takahashi S. , et al. Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res 2015; 45 (04) 378-386
  • 52 Kubo K, Kimura T, Aikata H. , et al. Long-term outcome of stereotactic body radiotherapy for patients with small hepatocellular carcinoma. Hepatol Res 2018; 48 (09) 701-707
  • 53 Kwon JH, Bae SH, Kim JY. , et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 2010; 10: 475
  • 54 Scorsetti M, Comito T, Cozzi L. , et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol 2015; 141 (07) 1301-1309
  • 55 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391 (10127): 1301-1314
  • 56 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
  • 57 Llovet JM, Real MI, Montaña X. , et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319) 1734-1739
  • 58 Lo C-M, Ngan H, Tso W-K. , et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 (05) 1164-1171
  • 59 Brown KT, Do RK, Gonen M. , et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 2016; 34 (17) 2046-2053
  • 60 Meyer T, Kirkwood A, Roughton M. , et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 2013; 108 (06) 1252-1259
  • 61 Lee EW, Khan S. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma. Clin Mol Hepatol 2017; 23 (04) 265-272
  • 62 Sapir E, Tao Y, Schipper MJ. , et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2018; 100 (01) 122-130
  • 63 Feng M, Suresh K, Schipper MJ. , et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. JAMA Oncol 2018; 4 (01) 40-47
  • 64 Llovet JM, Bustamante J, Castells A. , et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29 (01) 62-67
  • 65 Yao FY, Bass NM, Nikolai B. , et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9 (07) 684-692
  • 66 Fujii T, Takayasu K, Muramatsu Y. , et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 1993; 23 (02) 105-109
  • 67 Bruix J, Raoul J-L, Sherman M. , et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012; 57 (04) 821-829
  • 68 Cheng A-L, Kang Y-K, Chen Z. , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (01) 25-34
  • 69 Llovet JM, Ricci S, Mazzaferro V. , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390
  • 70 Niu Z-J, Ma Y-L, Kang P. , et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol 2012; 29 (04) 2992-2997
  • 71 Luo J, Guo R-P, Lai ECH. , et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18 (02) 413-420
  • 72 Silva JP, Berger NG, Tsai S. , et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB 2017; 19 (08) 659-666
  • 73 Tse RV, Hawkins M, Lockwood G. , et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26 (04) 657-664
  • 74 Bujold A, Massey CA, Kim JJ. , et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013; 31 (13) 1631-1639
  • 75 Culleton S, Jiang H, Haddad CR. , et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014; 111 (03) 412-417
  • 76 Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiother Oncol 2018; 129 (01) 112-122
  • 77 Kang J, Nie Q, Du R. , et al. Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Mol Clin Oncol 2014; 2 (01) 43-50
  • 78 Yoon SM, Ryoo B-Y, Lee SJ. , et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol 2018; 4 (05) 661-669
  • 79 Chow PKH, Gandhi M, Tan SB. , et al; Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 2018; 36 (19) 1913-1921
  • 80 Ricke J, Sangro B, Amthauer H. , et al. The impact of combining selective internal radiation therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the SORAMIC trial palliative cohort. J Hepatol 2018; 68: S102
  • 81 Vilgrain V, Pereira H, Assenat E. , et al; SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with Yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017; 18 (12) 1624-1636
  • 82 Huang J, Yan L, Cheng Z. , et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010; 252 (06) 903-912
  • 83 Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl 2015; 21 (09) 1142-1152
  • 84 Andolino DL, Johnson CS, Maluccio M. , et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011; 81 (04) e447-e453
  • 85 Moore A, Cohen-Naftaly M, Tobar A. , et al. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable hepatocellular carcinoma. Radiat Oncol 2017; 12 (01) 163
  • 86 Sandroussi C, Dawson LA, Lee M. , et al. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int 2010; 23 (03) 299-306
  • 87 Facciuto ME, Singh MK, Rochon C. , et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol 2012; 105 (07) 692-698
  • 88 Mannina EM, Cardenes HR, Lasley FD. , et al. Role of stereotactic body radiation therapy before orthotopic liver transplantation: retrospective evaluation of pathologic response and outcomes. Int J Radiat Oncol Biol Phys 2017; 97 (05) 931-938
  • 89 Hasan S, Thai N, Uemura T. , et al. Hepatocellular carcinoma with child Pugh-A Cirrhosis treated with stereotactic body radiotherapy. World J Gastrointest Surg 2017; 9 (12) 256-263
  • 90 Mohamed M, Katz AW, Tejani MA. , et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol 2015; 1 (01) 35-42
  • 91 Price TR, Perkins SM, Sandrasegaran K. , et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer 2012; 118 (12) 3191-3198
  • 92 Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys 2012; 83 (03) 895-900
  • 93 Sapisochin G, Barry A, Doherty M. , et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017; 67 (01) 92-99
  • 94 O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012; 18 (08) 949-954
  • 95 Guarneri A, Franco P, Romagnoli R. , et al. Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma. Radiol Med (Torino) 2016; 121 (11) 873-881
  • 96 Nugent FW, Gunturu K, Stuart KE, Flacke S, Molgaard C, Hunter K. A randomized phase II study of individualized stereotactic body radiotherapy (SBRT) versus transarterial chemoembolization (TACE) with DEBDOX beads as a bridge to transplant in hepatocellular carcinoma (HCC). J Clin Oncol 2017; 35 (15, supp): 223
  • 97 Klein J, Dawson LA, Jiang H. , et al. Prospective longitudinal assessment of quality of life for liver cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2015; 93 (01) 16-25
  • 98 Kellock T, Liang T, Harris A. , et al. Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: imaging evaluation post treatment. Br J Radiol 2018; 91 (1085): 20170118
  • 99 Maturen KE, Feng MU, Wasnik AP. , et al. Imaging effects of radiation therapy in the abdomen and pelvis: evaluating “innocent bystander” tissues. Radiographics 2013; 33 (02) 599-619